Charles Schwab
BSTG

Charles Schwab’s Biostage, Inc. Common Stock BSTG Stock Holding History

Charles Schwab’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-37,125
Closed -$337K – 3174
2014
Q1 		$337K Hold
37,125
– – ﹤0.01% 2753
2013
Q4 		$177K Buy
+37,125
New +$174K ﹤0.01% 2981

Other funds holding BSTG

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Charles Schwab's BSTG Position: Q2 2014 in Review

Charles Schwab sold out of Biostage, Inc. Common Stock (BSTG) in Q2 2014, closing a stake of 37,125 shares — an estimated $337K sold.

Charles Schwab first reported a position in BSTG in Q4 2013 and held it in 2 quarters. The position peaked at $337K in Q1 2014. 53 funds tracked by Wall St. Rank hold BSTG as of Q2 2014.

  • Charles Schwab reported no remaining Biostage, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Charles Schwab sold 37,125 Biostage, Inc. Common Stock shares in Q2 2014, an estimated $337K.
  • Charles Schwab first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 2 quarters.
  • Charles Schwab's Biostage, Inc. Common Stock position peaked at $337K in Q1 2014.
  • 53 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q2 2014.

Based on Charles Schwab's 13F filing for Q2 2014, filed 30 Jul 2014.